Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue grows, but more slowly than its trailing trend

Q1 FY2026 cost of revenue of $1.33M rose 5.3% year over year, behind the +19.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 16.6% from the prior quarter. Over 3 fiscal years it compounded at +13.1% a year.

Context

  • Cost of revenue amounted to 12.7% of revenue in FY2025, up 3.9 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.3% toward the trailing-twelve-month pace of +19.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.33M-16.6% QoQ
Last fiscal yearDec 2025
$6.57M+16.9% YoY
LTMMar 2026
$6.64M+19.4% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.3%——
1 year+16.9%——
3-year CAGR+13.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
6.57M USD
Year-over-year change
+16.9%
4-year CAGR
+10.5%

Cost of Revenue vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +19.4% is the 4th highest of 8, against a peer median of +8.0%.
  • Cost of revenue amounts to 12.8% of revenue for OCUL, versus a peer median of 24.7%.
OCUL Competitors
Cost of Revenue for OCUL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$2.28B USD+8.0%+15.0%42.8%
GKOSGlaukos CorporationLTM Jun 2026$127.96M USD+24.9%+18.3%20.9%
HROWHarrow Health, Inc.LTM Mar 2026$69.57M USD+28.3%+38.8%25.9%
STAASTAAR Surgical CompanyLTM Apr 2026$68.44M USD-5.7%-2.2%23.6%
OCSOculis Holding AGLTM Mar 2026CHF 15.07M CHF——2989.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026$6.64M USD+19.4%+13.1%12.8%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$1.79M USD-52.4%-37.2%23.5%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$1.54M USD+977.1%+54.6%460.9%
SGPSpyGlass Pharma, Inc. Common StockFY2025$612K USD———
KODKodiak Sciences Inc.LTM Sep 2026$0 USD-100.0%——
OCGNOcugen, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OCUL) —+8.0%+16.6%24.7%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.